FDA will expedite review of Vanda's sleep-disorder drug tasimelteon

07/31/2013 | Bloomberg

The FDA granted priority-review status to Vanda Pharmaceuticals' regulatory application for tasimelteon, an experimental treatment for blind people with the non-24-hour disorder. If approved, tasimelteon will be the first drug cleared for the condition. A decision is expected by Jan. 31.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA